Business & Regulation

It’s time to go back to basics when it comes to pharmaceutical supply chains and preventing shortages.

What trends and disruptions will shape the future of pharma? West’s Anya Harry gives her view.

Why some stakeholders are not happy about the FDA’s removal of tirzepatide from the drug shortage list.

The highlights of the trade show and its conference agenda - day 3

The highlights of the trade show and its conference agenda - day 2

The highlights of the trade show and its conference agenda - day 1

Here’s a look at recent violations cited in FDA Warning Letters: fly pupae, cross contamination, trial dosing errors, and more.

Michael Altorfer, CEO, Swiss Biotech Association, gives his view on the future of drug development.

We asked over 100 industry professionals for their views on the future of the pharma and biopharma industries.

Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review.